Historical coo News Stories
COO Q1 Beat: Guidance Raised, Buybacks Accelerate.
CooperCompanies reported a solid Q1 with revenue of $1.024B, stronger margins and an upwardly revised FY26 guidance. With $92.5M in share repurchases and improved operating leverage, the stock reaction hinges on execution in CooperVision and CooperSurgical ahead.
CooperCompanies: Vision Sales Lift COO Share Rally
CooperCompanies (COO) saw a roughly 5% stock uptick after stronger-than-expected contact-lens sales, while a recent term-loan amendment extends debt maturities and expands borrowing flexibility. Together, these developments strengthen near-term cash-flow outlook and strategic optionality for the company.
COO Stock Surges on Q1 Beat, MiSight Uptake Gains!
CooperCompanies (COO) reported a strong fiscal Q1 2026 with a revenue beat, raised guidance, accelerating CooperVision growth driven by MyDay and MiSight, and disciplined cash deployment including buybacks and debt reduction—providing clear, near-term catalysts for the stock.
CooperCompanies: Board Shakeup Spurs COO Rally Now
CooperCompanies (COO) saw a governance change and launched a formal strategic review the past week, accompanied by strong Q4 results, an expanded buyback program and bullish 2026 guidance—moves that pushed shares higher and prompted analyst target upgrades. This article breaks down the concrete developments, financials, and investor implications for the vision-care and women’s-health business units.
COO Upside: March 5 Earnings & Board Shakeup Ahead
CooperCompanies (COO) faces a pivotal week as it reports Q1 on March 5. Board leadership changes, a formal strategic review and activist cooperation have set clear near-term catalysts.
CooperCompanies COO: Board Shakeup Fuels Value Up
CooperCompanies (COO) has moved decisively on governance and capital allocation: a board refresh linked to activist Browning West, fiscal 2025 results showing modest organic growth, a $1B bump to buyback capacity, and a strategic review that could reshape CooperVision and CooperSurgical. These concrete actions — plus FY2026 guidance and cost-savings targets — create a clearer near-term playbook for investors.